D-cycloserine for Relapse Prevention Following Intravenous Ketamine in Treatment-resistant Depression

This is a two-stage experiment;

The first stage is an open label trial in which participants receive six intravenous (IV) treatments of ketamine.

The second stage includes participants that responded to ketamine (i.e. reduction of 25% in their symptoms of depression, as measured by the Montgomery Asberg Depression Scale MADRS). The second stage is a double-blind, controlled clinical trial of D-cycloserine (DCS) vs. placebo, as maintenance treatment in patients who responded to ketamine treatment.

The aim of the study is to determine whether 8 weeks of DCS maintenance therapy will prevent relapse of depressive symptoms following ketamine infusions.

Topic Treatment-Resistant Depression
Compound Placebo Ketamine
Country Israel
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

Sheba Medical Center
This company doesn't have a full profile yet, it is linked to a clinical trial.

Teva Pharmaceuticals USA
This company doesn't have a full profile yet, it is linked to a clinical trial.

Tel Aviv University
The Institute for Integrative Psychedelic Research at Tel Aviv University (IPR-TLV) aims to revolutionize mental health through the interdisciplinary study of psychedelics.

Measures Used

Montgomery-Asberg Depression Rating Scale
A ten-item diagnostic questionnaire used to measure the severity of depressive symptoms in patients with mood disorders.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.